Compare Manhattan Associates Inc (MANH) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Viatris Inc — how do they compare? Manhattan Associates Inc trades at $166.09 (market cap $9.79B), while Viatris Inc trades at $17 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 2× Manhattan Associates Inc's market cap, and Viatris Inc pays a 2.83% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals.
| MANH | VTRS | |
|---|---|---|
Market Cap | $9.79B | $19.79B |
Sector | Technology | Health |
52-Week High | $227.94 | $17.39 |
52-Week Low | $120.88 | $8.74 |
Enterprise Value | $9.62B | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manhattan Associates (MANH) trades at $165.51, up 1.42% today, with a bullish technical outlook supported by moving averages and strong support at $162. The company demonstrates robust fundamentals with a 19.68% net margin and consistent earnings beats in recent quarters. Analyst sentiment remains positive with 73% buy ratings and a $192.80 consensus target, though an ongoing legal investigation has generated negative news flow.
MANH presents a growth opportunity with high profitability and earnings momentum, but faces near-term risks from legal scrutiny and premium valuations. The stock's technical strength and fundamental performance support upside potential, though investors should weigh the legal overhang against strong operational execution.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
